We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Mutation Provides Clue to Vibratory Urticaria

By LabMedica International staff writers
Posted on 15 Feb 2016
Print article
The Phadia ImmunoCAP 100 immunoassay analyzer
The Phadia ImmunoCAP 100 immunoassay analyzer (Photo courtesy of Thermo Fisher Scientific)
Patients with autosomal dominant vibratory urticaria have localized hives and systemic manifestations in response to dermal vibration, with coincident degranulation of mast cells and increased histamine levels in serum.

Genetic mutation have been discovered that underlies this rare disorder which manifests as itchy red welts, or hives, and other allergic symptoms such as flushing, headaches, fatigue, blurry vision or a metallic taste in the mouth can then occur. Although these symptoms normally fade within an hour, the reaction may occur several times a day.

Scientists at the US National Institutes of Health (NIH; Bethesda, MD, USA) evaluated three families who have experienced the disorder through several generations. The evaluation included a forearm vortex challenge, serum histamine measurements, and findings on skin biopsies. They performed genetic analysis of the families with vibratory urticaria by means of linkage scans, exome sequencing, and Sanger sequencing.

Serum histamine levels were measured from serial blood draws during the 60 minute post vortex challenge period using a competitive enzyme immunoassay (SPI-Bio; Montigny le Bretonneux, France). Serum tryptase levels from the same time points were measured using the ImmunoCAP 100 system (Phadia; Uppsala, Sweden). Immunohistochemistry was performed using the Discovery XT instrument with RedMap detection kit (Ventana Medical Systems; Tucson, AZ, USA). Polymerase chain reaction (PCR) and Sanger sequencing were performed according to standard protocols. The teams carried out DNA sequencing on 36 affected and unaffected members of the three families.

The scientists found a single mutation in the Adhesion G Protein-Coupled Receptor E2 (ADGRE2) gene that was shared by family members with vibratory urticaria but not present in unaffected people. The ADGRE2 gene provides instructions for production of ADGRE2 protein, present on the surface of several types of immune cells, including mast cells. In ADGRE2, there is a beta subunit inside the cell's outer membrane and an alpha subunit on the outer surface of the cell. Normally, these two subunits interact, staying close together, but in people with vibratory urticaria, the team observed a less stable interaction. When the subunits separate, the investigators believe that the beta subunit produces signals inside mast cells that lead to degranulation. This is what leads to hives and other allergy symptoms. The study was published on February 3, 2016, in the New England Journal of Medicine (NEJM).

Related Links:

US National Institutes of Health
SPI-Bio
Phadia 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more